Richard Garfinkel, MD
Retina Specialist · Chevy Chase, MDNPI 1831163997
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Notal Vision, Inc. at 31.8% of the total.
Across 83 payments — averaging $57.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Notal Vision, Inc.$2K
- Genentech USA, Inc.$432
- Apellis Pharmaceuticals, Inc.$430
- Alimera Sciences, Inc.$271
- AbbVie$268
- Novartis$225
- plus $2K from 13 others
Across 328 payments — averaging $34.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$11K
What the payments were for
- Speaking & faculty fees$1162%
- Food & beverage$4,62098%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Notal Vision, Inc. | 8 | $1,505 |
| Genentech USA, Inc. | 13 | $432 |
| Apellis Pharmaceuticals, Inc. | 8 | $430 |
| Alimera Sciences, Inc. | 5 | $271 |
| AbbVie(2 entities) | 9 | $268 |
| Novartis | 6 | $225 |
| Regeneron Healthcare Solutions, Inc. | 7 | $224 |
| Astellas Pharma US Inc | 4 | $174 |
| Alcon | 2 | $153 |
| Biotissue Holdings Inc. | 1 | $137 |
| Tarsus Pharmaceuticals, Inc. | 1 | $136 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Dompe US, Inc. | 1 | $125 |
| Shire North American Group Inc | 1 | $123 |
| Bausch & Lomb Americas Inc. | 6 | $116 |
| Eyepoint US, Inc. | 5 | $100 |
| Dutch Ophthalmic, USA | 1 | $88 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $64 |
| Harrow Eye, LLC | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,736 in reported general payments places this provider in the 70th percentile of 47 retina specialist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 22 | $475 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Chevy Chase
- Brian DoChevy Chase$116K
- Michael LaiChevy Chase$13K
- Gayatri ReillyChevy Chase$2K
- Daniel BerinsteinChevy Chase$1K
- Rohit LakhanpalOwings Mills$168K
- Adam GerstenblithHagerstown$107K
- Aziz KhanifarSilver Spring$83K
- Michael ElmanBaltimore$27K
- Reginald SandersGreenbelt$24K
- Sidney SchechetBaltimore$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.